| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Dihydrolapachenole is a naturally occurring quinone. Its biological targets are not well characterized. As a quinone, it may have redox activity and interact with cellular electron transport systems. It may have antioxidant or cytotoxic activities.
|
|---|---|
| ln Vitro |
In vitro, Dihydrolapachenole is a naturally occurring quinone. It is isolated from T. chrysantha. Detailed in vitro activity data are limited. It may have antioxidant or cytotoxic properties due to its quinone structure.
|
| ln Vivo |
In vivo studies for Dihydrolapachenole are limited. As a quinone, it may have pharmacological activities including antioxidant or anticancer effects. Animal studies are needed to confirm its in vivo efficacy and safety.
|
| Enzyme Assay |
Cell-free assays for Dihydrolapachenole: antioxidant activity is measured using DPPH, ABTS, and FRAP assays. Redox activity is assessed by cyclic voltammetry or by measuring reduction of tetrazolium salts. Enzyme inhibition assays can be performed using standard protocols. Cytotoxicity is evaluated using cell-free systems.
|
| Cell Assay |
Cellular assays for Dihydrolapachenole: cancer cell lines and normal cells are cultured and treated with Dihydrolapachenole at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is measured by MTT assay. ROS production is measured using DCFH-DA. Apoptosis is assessed by Annexin V/PI staining.
|
| Animal Protocol |
In vivo animal studies for Dihydrolapachenole: animal models of cancer or oxidative stress would be used. Animals are administered Dihydrolapachenole orally or intraperitoneally at doses of 10-50 mg/kg. Tumor growth, oxidative stress markers, and toxicity are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Dihydrolapachenole: as a small lipophilic molecule (molecular weight 242.31), it may have good oral bioavailability and tissue penetration. It is likely metabolized in the liver and excreted via the kidneys. Detailed PK data are limited.
|
| Toxicity/Toxicokinetics |
Toxicity of Dihydrolapachenole: comprehensive toxicity data are limited. As a quinone, it may have cytotoxic effects at high doses due to redox cycling and ROS production. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
Dihydrolapachenole is a research compound with potential applications in natural product research. It is available as a reference standard for pharmacological studies. Its mechanism may involve redox activity typical of quinones. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C16H18O2
|
|---|---|
| Molecular Weight |
242.31
|
| Exact Mass |
242.131
|
| CAS # |
20213-26-7
|
| PubChem CID |
849479
|
| Appearance |
White to off-white solid
|
| LogP |
3.952
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
300
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COc1cc2CCC(C)(C)Oc2c2ccccc12
|
| InChi Key |
OZVDAMFCGBFOHR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H18O2/c1-16(2)9-8-11-10-14(17-3)12-6-4-5-7-13(12)15(11)18-16/h4-7,10H,8-9H2,1-3H3
|
| Chemical Name |
6-methoxy-2,2-dimethyl-3,4-dihydrobenzo[h]chromene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1269 mL | 20.6347 mL | 41.2694 mL | |
| 5 mM | 0.8254 mL | 4.1269 mL | 8.2539 mL | |
| 10 mM | 0.4127 mL | 2.0635 mL | 4.1269 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
